FKBP12 loss was significantly correlated with worse OS and DFS in TNBC patients (n = 88, P = 0.0009 and P = 0.0007, respectively) (Fig. 2d), but not in the overall population (n = 524, P >0.05) (Fig. 2a), in patients with luminal breast cancer (n = 334, P >0.05) (Fig. 2b), or in patients with HER2+ breast cancer (n = 102, P >0.05) (Fig. 2c). Here, ERBB2 is linked to breast carcinoma.